{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:08:41Z","timestamp":1790507321839,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106072","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:42:33Z","timestamp":1593780153000},"page":"106072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-4236","authenticated-orcid":false,"given":"Temi","family":"Lampejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106072_bib0001","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for Gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0002","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0004","first-page":"49","article-title":"Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens","volume":"4","author":"Das","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jac\/dkm211","article-title":"Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus","volume":"60","author":"Saravolatz","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dki006","article-title":"Pharmacokinetics and excretion of dalbavancin in the rat","volume":"55","author":"Cavaleri","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY antimicrobial surveillance program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0009","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0011","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/jac\/dkz006","article-title":"Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres","volume":"74","author":"Sader","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0012","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0013","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2 year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in Gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0016","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On and off label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0017","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: a high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0021","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0022","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijid.2019.12.008","article-title":"Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report","volume":"91","author":"Hakim","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ofid\/ofz427","article-title":"Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report","volume":"6","author":"Spaziante","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/CMR.1.1.19","article-title":"Serum bactericidal test","volume":"1","author":"Stratton","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","article-title":"Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin","volume":"82","author":"Jones","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0026","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0027","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/jac\/dkq335","article-title":"Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia","volume":"65","author":"Pfaller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0028","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10096-016-2865-8","article-title":"Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011\u20132014)","volume":"36","author":"Mendes","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0029","first-page":"183","article-title":"Clinical experience with telavancin: real-world results from the telavancin observational use registry (TOURTM)","volume":"6","author":"Bressler","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0030","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.49.8.3163-3165.2005","article-title":"Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus","volume":"49","author":"Madrigal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0031","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/jac\/dkw249","article-title":"Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains","volume":"71","author":"Xiong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01877-16","article-title":"Telavancin is active against experimental aortic valve endocarditis caused by daptomycin- and methicillin-resistant Staphylococcus aureus strains","volume":"61","author":"Abdelhady","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02489-16","article-title":"Efficacy of telavancin alone & in combination with ampicillin in a rat model of enterococcus faecalis endocarditis","volume":"61","author":"Tran","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0034","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0035","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/jac\/dkr234","article-title":"Successful treatment of methicillin resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure","volume":"66","author":"Joson","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0036","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1128\/AAC.00857-10","article-title":"Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin","volume":"54","author":"Marcos","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0037","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jac\/dkq113","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin","volume":"65","author":"Nace","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0038","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/23744235.2017.1300318","article-title":"Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports","volume":"49","author":"Thompson","year":"2017","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0039","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0040","unstructured":"ClinicalTrials.gov Identifier: NCT03148756. Efficacy and safety of dalbavancin compared to standard of care antibiotic therapy for the completion of treatment of patients with complicated bacteremia or infective endocarditis. n.d."},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0041","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1093\/ofid\/ofz360.822","article-title":"Evaluation of standardized dalbavancin use to facilitate early hospital discharge for patients inappropriate for outpatient parenteral antibiotic therapy","volume":"6","author":"Shihadeh","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0042","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0043","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(03)15266-X","article-title":"Infective endocarditis","volume":"363","author":"Moreillon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0044","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archinternmed.2008.603","article-title":"Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century","volume":"169","author":"Murdoch","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0045","article-title":"Long-term outcomes of injection drug-related infective endocarditis among people who inject drugs","author":"Suzuki","year":"2019","journal-title":"J Addict Med"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0046","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jac\/dky474","article-title":"Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy","volume":"74","author":"Underwood","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0047","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0048","first-page":"2021","article-title":"Oral antibiotics for infective endocarditis: a clinical review","volume":"75","author":"Brown","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0049","first-page":"3075","article-title":"ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC): endorsed by: European Association for Cardio-thoracic Surgery (EACTS)","volume":"36","author":"Habib","year":"2016","journal-title":"Russ J Cardiol"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0050","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0051","first-page":"386","article-title":"Practice patterns of infectious diseases physicians in transitioning from intravenous to oral therapy in patients with bacteremia","author":"Hospenthal","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0052","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.drugalcdep.2019.03.013","article-title":"The optimization of methadone dosing whilst treating with rifampicin: a pharmacokinetic modeling study","volume":"200","author":"Badhan","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0053","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0054","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin\u2010resistant and methicillin\u2010susceptible Staphylococcus aureus bacteremia: a meta\u2010analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","article-title":"Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus","volume":"45","author":"Boucher","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0056","year":"2020","journal-title":"A phase 3 multicenter, randomized, open-label, clinical trial of telavancin versus standard intravenous therapy in the treatment of subjects with Staphylococcus aureus bacteremia including infective endocarditis"},{"key":"10.1016\/j.ijantimicag.2020.106072_bib0057","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jclinepi.2005.04.003","article-title":"Case reports and case series from Lancet had significant impact on medical literature","volume":"58","author":"Albrecht","year":"2005","journal-title":"J Clin Epidemiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:35:19Z","timestamp":1760376919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920302429"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106072","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106072"}}